A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in   folate receptor alpha (FR alpha)-high recurrent ovarian cancer eligible   for platinum-based chemotherapy.

Titel:: A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FR alpha)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
Dokumenttyp:: Meeting Abstract
Autor(en):: Trillsch, Fabian; Schochter, Fabienne; Park-Simon, Tjoung-Won; Reuss, Alexander; Fehm, Tanja N.; Wimberger, Pauline; Bronger, Holger; Schmalfeldt, Barbara; Sehouli, Jalid; Marme, Frederik; Heitz, Florian; Mahner, Sven; Fredrich, Michaela; Barth, Stefanie; Stec, James Joseph; Method, Michael W.; Harter, Philipp
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2022
Band / Volume:: 40 Suppl S
Heft / Issue:: 16
Print-ISSN:: 0732-183X
TUM Einrichtung:: Klinik und Poliklinik für Frauenheilkunde
BibTeX

Vorkommen: